But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic ...

Novo Nordisk has launched its blockbuster diabetes drug Ozempic in India, pricing the starter dose at ₹8,800 per month (₹2,200 per week), positioning it as a competitor to Eli Lilly's Mounjaro (priced ...

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

The House has spent much of the last two months of this year trying to catch up on its work. It passed 22 bills in one recent ...

The Delhi High Court ruled against Novo Nordisk's request to block Dr Reddy's production of semaglutide for export. The case ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Danish pharmaceutical company Novo Nordisk has launched its blockbuster diabetes and weight-related therapy Ozempic in India, ...